FDA approves two new long-acting insulin products
The U.S. Food and Drug Administration (FDA) and Novo Nordisk on Sept. 25 announced the approval of two products containing the long-acting human basal insulin and analog insulin degludec, to improve blood glucose control in adults with type 1 or 2 diabetes. Read More »